GKOS vs BIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

GKOS

72.3
AI Score
VS
GKOS Wins

BIO

51.0
AI Score

Investment Advisor Scores

GKOS

72score
Recommendation
BUY

BIO

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GKOS BIO Winner
Revenue 336.18M 1.24B BIO
Net Income -38.16M -155.70M GKOS
Gross Margin 80.0% 52.7% GKOS
Net Margin -11.4% -12.5% GKOS
Operating Income -37.12M 106.70M BIO
ROE -5.6% -2.2% BIO
ROA -4.1% -1.5% BIO
Total Assets 920.52M 10.25B BIO
Cash 114.48M 517.00M BIO
Current Ratio 5.04 3.14 GKOS
Free Cash Flow -4.40M 144.80M BIO

Relative Price Performance (Last 90 Days)

GKOS 1M: -8.8% · 3M: +10.1% BIO 1M: -5.0% · 3M: +25.1%

Current Technical Phase

GKOS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 46.9 · Price: $163.75

BIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.4 · Price: $369.14

Fundamentals Snapshot

Metric GKOS BIO
Market Cap — —
Forward P/E 324.5 37.2
Trailing P/E — 43.4
Revenue (TTM) — —
Revenue Growth 0.5% 0.0%
Gross Margin 0.8% 0.5%
Operating Margin -0.1% 0.1%
EPS -3.25 8.20
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GKOS is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.